Published in Cancer Weekly, October 18th, 1999
Researchers in Johannesburg, South Africa, discovered that administration of estrogen to women who had undergone surgery for ovarian cancer did not make them more susceptible to recurrence of the cancer than other patients, who did not receive the medication. Hence, ERT did not hinder the postoperative disease-free interval or the overall chances for survival. (Guidozzi, F., and Daponte, A., "Estrogen Replacement Therapy for Ovarian Carcinoma Survivors: A Randomized...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.